Pediatrix Medical Group, Inc. (NYSE:MD) Given Consensus Rating of “Hold” by Analysts

Pediatrix Medical Group, Inc. (NYSE:MD) has been given an average rating of “Hold” by the six ratings firms that are presently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $17.08.

A number of analysts have weighed in on the stock. Jefferies Financial Group increased their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. StockNews.com upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research note on Wednesday, January 22nd. Deutsche Bank Aktiengesellschaft boosted their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Truist Financial raised their price objective on Pediatrix Medical Group from $15.00 to $18.00 and gave the stock a “hold” rating in a research report on Friday. Finally, Macquarie assumed coverage on shares of Pediatrix Medical Group in a report on Monday, December 16th. They set an “outperform” rating and a $18.00 price objective for the company.

Pediatrix Medical Group Price Performance

Shares of MD opened at $15.57 on Wednesday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.42 and a current ratio of 1.60. The firm has a market cap of $1.34 billion, a PE ratio of -12.97, a PEG ratio of 1.74 and a beta of 1.57. The firm’s 50 day moving average price is $13.89 and its 200 day moving average price is $13.01. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $17.67.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Thursday, February 20th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.37 by $0.12. The company had revenue of $502.36 million for the quarter, compared to the consensus estimate of $486.22 million. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. As a group, research analysts expect that Pediatrix Medical Group will post 1.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Pediatrix Medical Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mackenzie Financial Corp acquired a new position in shares of Pediatrix Medical Group during the 4th quarter worth about $276,000. PharVision Advisers LLC bought a new position in shares of Pediatrix Medical Group during the 4th quarter worth approximately $245,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Pediatrix Medical Group by 7.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 256,335 shares of the company’s stock worth $3,363,000 after acquiring an additional 18,627 shares during the last quarter. Voloridge Investment Management LLC bought a new stake in Pediatrix Medical Group in the 4th quarter valued at $396,000. Finally, Squarepoint Ops LLC acquired a new stake in Pediatrix Medical Group during the 4th quarter valued at $132,000. 97.71% of the stock is owned by institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.